Satellite Bio
A biotech startup spun out of MIT and Boston University needed to translate 20 years of cell therapy research into an investor-ready vision deck. We designed a narrative that made the science feel as inevitable as the opportunity—reimagining how cells become medicines.
Reimagining Cell Therapy
CAR-T cell therapy has transformed cancer treatment, driving $1.6B+ in venture investment. But a fundamental limitation remained: only immune cells survive infusion. Solid organ cells—the ones that could treat the widest range of diseases—fail to engraft, vascularize, and persist in the body.
Satellite Bio's SAT Platform solves this with a first-in-class tissue therapeutics approach: heterocellular aggregation, pro-engraftment encapsulation, scalable manufacturing, and anatomical placement via their proprietary SAT-Map Atlas. The deck needed to make investors feel the weight of the science and the scale of the market—without losing them in the complexity.
The Landscape We Visualized
Key data points that shaped the narrative architecture of the deck
CAR-T Venture Capital
Investment surge since the first approved cell therapy—validating the market Satellite Bio is entering.
CAR-T Trial Starts
Clinical trials launched by 2021, showing exponential growth in the cell therapy space.
Research Foundation
Two decades of foundational research across MIT and Boston University unlocked the 4 key pillars of tissue therapeutics.
Platform Pillars
Aggregation, encapsulation, manufacturing, and anatomical placement—the SAT Platform's integrated architecture.
The Deck
